Darlington Cynthia L
Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand.
Curr Opin Investig Drugs. 2005 Jul;6(7):747-51.
Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. By April 2005, enrollment for phase II trials was complete, with results expected early in 2006.
Neurocrine生物科学公司正在研发NBI-5788，这是一种髓鞘碱性蛋白免疫显性表位的类似物，用于多发性硬化症的潜在静脉内治疗。到2005年4月，II期试验的入组工作已完成，预计2006年初得出结果。
